Skip to content

Study · In vitro (cells) · 2007

3 results

Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals.

Lezhava T, Jokhadze T

Annals of the New York Academy of Sciences1 Apr 2007Cited by 2 (Europe PMC)

PMID17460203 (opens in a new tab)DOI10.1196/annals.1395.043 (opens in a new tab)PepBankPUB-17460203
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In aged donor lymphocyte cultures, Livagen could induce chromatin reactivation through deheterochromatinization.

    In plain wordsIn lab tests with aged donor cells, Livagen could reactivate chromatin through deheterochromatinization.

    Peptide
    Livagen (KEDA)
    Outcome
    IncreaseChromatin reactivation
    Study

    humann: not reported in source

    Cultured lymphocytes from old individuals
    Outcome group
    Genome stability · Aging and longevity
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The peptide bioregulator Livagen could induce reactivation (deheterochromatinization) of chromatin to modify heterochromatinized chromosomal regions in cultured lymphocytes of aged individuals.
    1 context sentence
    Summary · context
    The functional characteristics of chromosomes (level of total heterochromatin, chromosome instability, and sister chromatid exchanges [SCEs]) were studied in cultured lymphocytes derived from 80- to 91-year-old and 18- to 30-year-old (control group) individuals under the single and combined effect o…
  2. 02LabIn vitro (cells)Efficacy outcome

    In old donor lymphocyte cultures, Livagen decreased cobalt-induced changes to 3.4 +/- 0.6%, versus 4.2 +/- 0.7% in controls.

    In plain wordsIn lab tests with old donor cells, Livagen reduced cobalt-induced chromosome changes compared with controls.

    Peptide
    Livagen (KEDA)
    Outcome
    DecreaseCobalt-induced chromosomal changes
    Study

    humann: not reported in source

    Cultured lymphocytes from old individuals
    Comparator
    Control group
    Outcome group
    Genome stability · Aging and longevity
    Studied dose
    Dose not stated

    Measurements

    Chromosomal changes
    3.4%
    Livagen
    Chromosomal changes
    4.2%
    control group

    Source sentences

    Summary
    The peptide bioregulator Livagen was effective in decreasing the number of changes induced by the CoCl(2) 3.4 +/- 0.6% (control group 4.2 +/- 0.7%).
    1 context sentence
    Summary · context
    The functional characteristics of chromosomes (level of total heterochromatin, chromosome instability, and sister chromatid exchanges [SCEs]) were studied in cultured lymphocytes derived from 80- to 91-year-old and 18- to 30-year-old (control group) individuals under the single and combined effect o…

Studies that did not test the peptide alone1

In this study, Livagen (KEDA) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Livagen (KEDA).

  1. 03LabNot a test of Livagen (KEDA) aloneIn vitro (cells)Mechanism

    In old donor lymphocyte cultures, cobalt with Livagen concentrated sister chromatid exchanges in telomeric heterochromatin, at 12.0 +/- 1.2% versus 2.8 +/- 0.5% in controls.

    In plain wordsIn lab tests with old donor cells, cobalt with Livagen increased telomeric sister chromatid exchanges compared with controls.

    Peptide
    Livagen (KEDA)
    Outcome
    IncreaseTelomeric sister chromatid exchange distribution
    Study

    humann: not reported in source

    Cultured lymphocytes from old individuals
    Comparator
    Control group
    Outcome group
    Genome stability · Aging and longevity

    Measurements

    Telomeric SCE
    12%
    CoCl(2) and Livagen
    Telomeric SCE
    2.8%
    control group

    Source sentences

    Summary
    while SCE were mostly registered in telomeric heterochromatin under the combined effect of CoCl(2) and Livagen 12.0 +/- 1.2% SCE (control group 4.5 +/- 0.6% and 2.8 +/- 0.5% SCE, respectively).
    1 context sentence
    Summary · context
    The functional characteristics of chromosomes (level of total heterochromatin, chromosome instability, and sister chromatid exchanges [SCEs]) were studied in cultured lymphocytes derived from 80- to 91-year-old and 18- to 30-year-old (control group) individuals under the single and combined effect o…

    In this study, Livagen (KEDA) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Livagen (KEDA).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 17:05 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.